Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
9 Dec 2019
Challenges and importance of long-term treatment for newly diagnosed multiple my...
Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin
Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients; community-based trial data ( Prof Sagar Lonial, Prof Meral Beksaç, Dr Robert Rifkin )
9 Dec 2019
Novel multi-antigen targeted CAR-NK cell for the treatment of B cell malignancie...
Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA
Novel multi-antigen targeted CAR-NK cell for the treatment of B cell malignancies ( Dr Bahram Valamehr - Fate Therapeutics Inc., San Diego, USA )
9 Dec 2019
Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise
Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA
Multiple myeloma: Anti-BCMA BiTE AMG 701 shows preclinical promise ( Dr Yu-Tzu Tai - Dana-Farber Cancer Institute, Boston, USA )
8 Dec 2019
Evaluating emerging mutations in patients with acute myeloid leukaemia who relap...
Dr Catherine Smith - University of California San Francisco, San Francisco, USA
Evaluating emerging mutations in patients with acute myeloid leukaemia who relapsed while receiving gilteritinib therapy in the ADMIRAL trial ( Dr Catherine Smith - University of California San Francisco, San Francisco, USA )
8 Dec 2019
Maintenance decitabine after intensive therapy for AML in older FLT3-ITD-negativ...
Dr James Foran - Mayo Clinic Florida, Jacksonville, USA
Maintenance decitabine after intensive therapy for AML in older FLT3-ITD-negative patients ( Dr James Foran - Mayo Clinic Florida, Jacksonville, USA )
8 Dec 2019
Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma
Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China
Bispecific CAR T-cell therapy as treatment for hard to treat multiple myeloma ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )
7 Dec 2019
Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma...
Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA
Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients ( Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA )
7 Dec 2019
CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissio...
Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China
CAR T-cell therapy in hard-to-treat multiple myeloma produces sustained remissions ( Dr Yu Hu - Huazhong University of Science and Technology, Wuhan, China )
7 Dec 2019
Dual-targeted antibody mosunetuzumab elicits durable responses in poor-prognosis...
Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA
Dual-targeted antibody mosunetuzumab elicits durable responses in poor-prognosis non-Hodgkin Lymphoma patients ( Prof Stephen Schuster - University of Pennsylvania, Philadelphia, USA )
7 Dec 2019
Updated recommendations for the management of elderly prostate cancer patients
Dr Helen Boyle - Le Centre Léon Bérard, Lyon, France
Updated recommendations for the management of elderly prostate cancer patients ( Dr Helen Boyle - Le Centre Léon Bérard, Lyon, France )
4 Dec 2019
JCOG: The Japan Clinical Oncology Group
Dr Tomonori Mizutani - Kyorin University, Mitaka, Tokyo
JCOG: The Japan Clinical Oncology Group ( Dr Tomonori Mizutani - Kyorin University, Mitaka, Tokyo )
4 Dec 2019